Held June 25-26, 2005,
the California PH Forum offers support and medical updates for patients,
their families, friends, and medical professionals interested in Pulmonary
Arterial Hypertension. It is presented in the years in between the Pulmonary Hypertension Association's biennial international conferences.
The PH Forum sessions
will feature Physicians, Nurses, and other Medical Professionals specializing
in PAH, and assisted by knowledgeable patients who will share their
experiences and hope with you.
On
July 4, 1999 our good friend Kipp Palmer passed away from complications
due to Primary Pulmonary Hypertension. Not only was Kipp a great golfer,
but he was a fighter who, in the end, couldn't prevail over PPH. Help
us remember Kipp on June 24th while contributing to the good cause
of PPH cure research.
PR
Pharmaceuticals' PulmoLAR(TM) Granted Orphan Drug Status
FORT COLLINS, Colo.,
May 12 /PRNewswire/ -- PR Pharmaceuticals Inc. (PRP), announced today
that the U.S. Food and Drug Administration (FDA) has granted orphan drug
designation for the Company's lead compound, 2-methoxyestradiol (2ME or
PulmoLAR(TM)), for the treatment of pulmonary arterial hypertension (PAH).
Pulmonary
Hypertension - A Patient's Survival Guide The premiere information resource
for people dealing with PH -- they have ARRIVED and are ready to
ship!!!
The author, a PH patient herself,
knows what it is like to live with the disease. She talked to many
other patients, doctors, and researchers while writing the Survival
Guide. Dr. Ronald J. Oudiz and a team of physicians with a deep
knowledge of PH edited the book for accuracy.
New edition contains a chart
of 15 drugs used to treat PH; results of recent
clinical trials;
in-depth discussion of PH secondary to other diseases
or conditions;
a new chapter on what to eat if you have PH; and much, much more!
Myogen Initiates Trial of Ambrisentan in Patients Who Previously Failed
Other ERA Therapy
DENVER, May 19 /PRNewswire-FirstCall/
-- Myogen, Inc. , a biopharmaceutical company focused on the discovery,
development and commercialization of small molecule therapeutics for
the treatment of cardiovascular disorders, today announced the initiation
of a clinical trial to evaluate ambrisentan in patients with pulmonary
arterial hypertension (PAH) who have previously discontinued bosentan
or sitaxsentan therapy due to liver function test (LFT) abnormalities,
specifically elevated serum aminotransferase concentrations.
The
information provided on the PHA website is provided for general information
only. It is not intended as legal, medical or other professional
advice, and should not be relied upon as a substitute for consultations
with qualified professionals who are familiar with your individual
needs.
On
July 4, 1999 our good friend Kipp Palmer passed away from complications
due to Primary Pulmonary Hypertension. Not only was Kipp a great golfer,
but he was a fighter who, in the end, couldn't prevail over PPH. Help
us remember Kipp on June 24th while contributing to the good cause
of PPH cure research.
